Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

PHASE2RecruitingINTERVENTIONAL
Enrollment

2,012

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2026

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

BIOLOGICAL

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Trial Locations (1)

1212

RECRUITING

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

PT Bio Farma

INDUSTRY

collaborator

Centers for Disease Control and Prevention

FED

collaborator

DiagnoSearch Life Sciences Pvt. Ltd.

UNKNOWN

lead

PATH

OTHER